This is not the most recent version of the article. View current version (5 JAN 2016)

Intervention Review

You have free access to this content

Omega-3 fatty acids for cystic fibrosis

  1. Colleen Oliver1,*,
  2. Helen Watson2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 27 NOV 2013

Assessed as up-to-date: 26 NOV 2013

DOI: 10.1002/14651858.CD002201.pub4


How to Cite

Oliver C, Watson H. Omega-3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD002201. DOI: 10.1002/14651858.CD002201.pub4.

Author Information

  1. 1

    The Royal Women's Hospital, Parkville, VIC, Australia

  2. 2

    Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge, UK

*Colleen Oliver, The Royal Women's Hospital, Grattan St & Flemington Rd, Parkville, VIC, 3052, Australia. cmckarney@yahoo.com.au. colleen.oliver@thewomens.org.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 27 NOV 2013

SEARCH

This is not the most recent version of the article. View current version (05 JAN 2016)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Henderson 1994 {published data only}
  • Henderson WR. Omega-3 supplementation in cystic fibrosis [abstract]. Proceedings of the 6th North American Cystic Fibrosis Conference; 1992 1992;Abstract Edition:S21.2.
  • Henderson WR Jr, Astley SJ, McCready MM, Kushmerick P, Becker JU, Ramsey B. Absorption of omega (w) -3 fatty acids in CF patients [abstract]. Pediatric Pulmonology 1992;Abstract Edition 2:311.
  • Henderson WR Jr, Astley SJ, McCready MT, Kushmerick P, Casey S, Becker JW, et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics 1994;124(3):400-8.
Keen 2010 {published data only}
  • Keen C, Olin A, Eriksson S, Ekman A, Lindblad A, Basu S, et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2010;50(5):537-44.
  • Keen C, Olin A, Eriksson S, Lindblad A, Ekman A, Basu S, Beerman C, Strandvik B. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s.
Lawrence 1993 {published data only}
  • Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993;342(8869):465-9.
  • Lawrence R, Sorrell T. Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis [abstract]. Australian and New Zealand Journal of Medicine 1993;23:442.
Panchaud 2006 {published data only}
  • Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Boulat O, et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo-controlled trial. Clinical Nutrition 2006;25(3):418-27.
  • Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Roule M. Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis 2005;4:S88.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Alicandro 2013 {published data only (unpublished sought but not used)}
  • Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzu G, Biffi A, et al. A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids 2013;88(2):163-9. [CFGD Register: GN118d; ]
  • Alicandro G, Gagliardini R, Rise P, Santini B, Biffi A, Tirelli S, et al. Oral DHA supplementation in children with CF: a randomized placebo-controlled study [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:394, Abstract no: 499. [CFGD Register: GN118c; ]
  • Alicandro G, Gagliardini R, Santini B, Rise P, Biffi A, Tirelli AS, et al. Oral DHA supplementation in children with cystic fibrosis: a randomized placebo-controlled study [abstract]. Journal of Cystic Fibrosis 2011;10 Suppl 1:S74, Abstract no: 290. [CFGD Register: GN118b; ]
  • Colombo C, Dacco V, Santini B, Garliardini R, Loi S, Casartelli M, et al. DHA supplementation in children affected by cystic fibrosis: an Italian, multicentre clinical trial [abstract]. Pediatric Pulmonology 2008;43 Suppl 31:427. [CFGD Register: GN118a]
Christophe 1992 {published data only}
  • Christophe A, Robberecht E, Franckx H. Effects of two different dietary supplements on eicosanoid precursor fatty acids in cystic fibrosis. 11th International Cystic Fibrosis Congress. 1992.
Katz 1996 {published data only}
  • Katz DP, Manner T, Furst P, Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 1996;12(5):334-9.
  • Manner T, Guida L, Katz DP, Askanazi J, Schlotzer E, Wiesse S. Parenteral fish oil administration in patients with cystic fibrosis [abstract]. Clinical Nutrition 1992;Abstract Edition(11):40.
  • Manner T, Katz DP, Askanazi J, Schlotzer E, Furst P. Parenteral fish oil administration in patients with cystic fibrosis [abstract]. Proceedings of the 17th Clinical Congress of ASPEN (American Society for Parenteral and Enteral Nutrition). 1993:440.
Koletzko 2000 {published data only}
  • Koletzko B, Tuxen-Mengedoht M, Muller I, Demmelmair H, Stern M, Steffan J. Polyunsaturated fatty acids improve outcome of cystic fibrosis patients [abstract]. Proceedings of the 13th International Cystic Fibrosis Conference; 2000 June 4-8; Stockholm. 2000:78.
  • Tuxen-Mengedoht M, Koletzko B, Demmelmair H, Knapp V, Stern M. Fish oil therapy in cystic fibrosis (CF): A randomised clinical trial [abstract]. Clinical Nutrition 1999;18(Suppl 1):54.
  • Tuxen-Mengedoht M, Koletzko B, Muller I, Demmelmair H, Knapp V, Stern M, et al. Fish-oil therapy in mucoviscidosis: A randomised double-blind study [abstract] [Fischol-Therapie bei Mukiviszidose: Eine randomisierte Doppelblindstudie]. Monatsschrift Fur Kinderheilkunde 1999;147(Suppl 2):107.
Kurlandsky 1994 {published data only}
Lloyd-Still 2006 {published data only}
  • Lloyd-Still J, Hoffman D, Arteburn L, Benisek D, Lester L. Lipid soluble antioxidant status during supplementation with algal docosahexaenoic acid triglyceride in CF [abstract]. Abstracts of the 24th European Cystic Fibrosis Conference. 2001:133.
  • Lloyd-Still J, Powers C, Hoffman D, Arterburn L, Benisek D, Lester L. Bioavailability and safety of an algal DHA triglyceride in cystic fibrosis [abstract]. Pediatric Research 2001;49:455a.
  • Lloyd-Still J, Powers C, Hoffman D, Boyd-Trull K, Lester L, Benisek D, et al. A randomised controlled study examining the bioavailability and safety of an algal docosahexaenoic acid (DHA) triacylglycerol in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):331.
  • Lloyd-Still J, Powers C, Hoffman D, Boyd-Trull K, Lester L, Benisek D, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomised controlled study. Nutrition 2006;22(1):36-46.
  • Lloyd-Still J, Powers C, Hoffman D, Boyd-trull K, Arterburn L, Benisek D, et al. Blood and tissue essential fatty acids after docosahexaenoic acid supplementation in cystic fibrosis [abstract]. Pediatric Pulmonology 2001;32(Suppl 22):263.
Romano 1997 {published data only}
  • Romano L, Gandino M, Fiore P, Shepherd D, Casciaro R, Coccia C, et al. Study on feasibility and results of midterm dietary supplementation in omega-3 fatty acids [abstract]. Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:167.
Starling 1988 {published data only}
  • Starling MB, Elliot RB. EPA and cystic fibrosis. Excerpta Medica, Asia Pacific Congress Series. 10th International Cystic Fibrosis Congress. 1988:74.
van Biervliet 2008 {published data only}
  • Van Biervliet S, Devos M, Delhaye J, Van Biervliet J, Robberecht E, Christophe A. Oral DHA supplementation in F508 homozygous cystic fibrosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids 2008;78(2):109-15.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
O'Sullivan 2011 {published data only}
  • O'Sullivan B, Baker D, Borowitz D, Comeau A, Cleveland R, Freedman S. The effect of formula fortified with docosahexaenoic acid (DHA) on infants with CF [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:401, Abstract no: 519. [CFGD Register: GN229; ]

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Benabdeslam 1998
  • Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. American Journal of Human Nutrition 1998;67(5):912-8.
CF Trust 2006
  • Littlewood J, Green M, Stannard W. Finding Out. CF Trust Factsheet 2006.
Cheng 1999
Corcoran 1937
  • Corcoran AC, Rabinowitch IM. A study of the blood lipids and blood proteins in Canadian Eastern Arctic Eskimos. Biochemistry Journal 1937;31:343-8.
Corey 1998
  • Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology 1998;41(6):583-91.
Dodge 1988
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Freedman 1999
  • Freedman SD, Alvarez JG. Pathogenesis of pancreatic disease in cystic fibrosis [abstract]. Pediatric Pulmonology 1999;Suppl 19:129.
Gaskin 1982
Gaszo 1989
  • Gazso A, Kaliman J, Horrobin DF, Sinzinger H. Effects of omega-3 fatty acids on the prostaglandin system in healthy probands. Wiener Klinische Wochenschrift 1989;101(8):283-8.
Higgins 2003
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hunt 1985
Imrie 1975
  • Imrie J, Fagan D, Sturgess J. Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and controlled subjects. American Journal Pathology 1975;95(3):697-708.
Jüni 2001
Konstan 1996
  • Konstan MW. Treatment of airway inflammation in cystic fibrosis. Current Opinion in Pulmonary Medicine 1996;2(6):452-6.
Lands 2007
Lloyd-Still 1996
Osterud 1995
Shwachman 1958
Wilmott 2000

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Beckles-Willson 2002
Oliver 2010
  • Oliver C, Everard M, N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD002201.pub2]
Oliver 2011